TheStreet Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to D+

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities researchers at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Wednesday, TheStreetRatingsTable reports.

Several other research analysts have also weighed in on TEVA. UBS Group reissued a “neutral” rating and issued a $11.00 price objective (down from $15.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 10th. JPMorgan Chase & Co. restated a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a research note on Sunday, March 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $11.08.

TEVA stock opened at $11.53 on Wednesday. The stock has a 50-day simple moving average of $10.63. Teva Pharmaceutical Industries has a 1-year low of $8.44 and a 1-year high of $13.30. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.66 and a current ratio of 1.03. The company has a market cap of $12.59 billion, a price-to-earnings ratio of -3.18, a PEG ratio of 0.89 and a beta of 1.46.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, April 28th. The company reported $0.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.08. Teva Pharmaceutical Industries had a positive return on equity of 21.65% and a negative net margin of 24.45%. The firm had revenue of $3.98 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the company posted $0.76 EPS. The business’s quarterly revenue was down 8.6% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries will post 2.54 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 40,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, May 21st. The stock was sold at an average price of $11.01, for a total transaction of $440,400.00. Following the completion of the transaction, the vice president now owns 33,128 shares in the company, valued at approximately $364,739.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP David Matthew Stark sold 37,884 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, May 11th. The shares were sold at an average price of $10.22, for a total value of $387,174.48. Following the transaction, the vice president now owns 40,858 shares of the company’s stock, valued at approximately $417,568.76. The disclosure for this sale can be found here. Insiders have sold a total of 205,128 shares of company stock valued at $2,255,252 in the last quarter. Company insiders own 0.56% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. Schroder Investment Management Group bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $359,000. Principal Financial Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 8.1% during the 1st quarter. Principal Financial Group Inc. now owns 128,772 shares of the company’s stock worth $1,486,000 after buying an additional 9,631 shares in the last quarter. Axiom Investment Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $353,000. Factorial Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 1,054.0% during the 1st quarter. Factorial Partners LLC now owns 1,788,700 shares of the company’s stock worth $155,000,000 after buying an additional 1,633,700 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Teva Pharmaceutical Industries by 527.2% during the 1st quarter. Squarepoint Ops LLC now owns 660,109 shares of the company’s stock worth $7,618,000 after buying an additional 554,855 shares in the last quarter. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Back-End Load

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.